Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Alpha Tau Medical Ltd ( (DRTS) ) is now available.
On January 6, 2026, Alpha Tau Medical reported final results from its first-in-human pancreatic ductal adenocarcinoma study in Montreal, showing an 81% disease control rate across 32 patients treated with its Alpha DaRT therapy, rising to 87% when excluding the first two low-dose feasibility patients, along with a 22–23% objective response rate and a favorable safety profile. Complementary data from 23 patients demonstrated preservation of key immune and inflammatory markers one month after treatment, including stable neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and a marked reduction in IL-6 levels, suggesting an immune-preserving, less inflammatory radiation profile that could support combination with systemic therapies such as chemotherapy or immunotherapy; these findings reinforce Alpha Tau’s strategic focus on pancreatic cancer, underpin ongoing U.S. and European trials, and may strengthen the company’s positioning as it seeks future regulatory approval for Alpha DaRT in this high-need indication.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn), which increases reliance on external funding despite improved balance-sheet solvency. Technicals are a meaningful offset with a strong uptrend and positive momentum, while valuation is not supportive given the negative P/E and lack of dividend yield.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016 that focuses on the research, development and potential commercialization of Alpha DaRT, an intratumoral diffusing alpha-emitters radiation therapy designed to deliver highly potent, localized alpha-irradiation to solid tumors while sparing surrounding healthy tissue. The company is advancing Alpha DaRT across multiple solid tumor indications through clinical trials in North America and Europe, aiming to establish the technology as a novel cancer treatment platform.
Average Trading Volume: 137,819
Technical Sentiment Signal: Buy
Current Market Cap: $445.1M
See more insights into DRTS stock on TipRanks’ Stock Analysis page.